Is PRTA or BHC more profitable?

Bausch Health Cos has a net margin of -11.47% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Bausch Health Cos -11.47% -2,922.77% 5.63%

Does the media refer more to PRTA or BHC?

In the previous week, Prothena had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Prothena and 1 mentions for Bausch Health Cos. Prothena's average media sentiment score of 1.56 beat Bausch Health Cos' score of 0.90 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bausch Health Cos 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRTA or TRVI?

In the previous week, Prothena had 5 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Prothena and 1 mentions for Trevi Therapeutics. Prothena's average media sentiment score of 1.56 beat Trevi Therapeutics' score of 0.46 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, PRTA or NBTX?

Nanobiotix has higher revenue and earnings than Prothena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 47.54 -$244.09M -$2.82 N/A Nanobiotix $36.87M 46.66 -$27.11M N/A N/A

Is PRTA or NBTX more profitable?

Nanobiotix has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Nanobiotix's return on equity of 0.00% beat Prothena's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Nanobiotix N/A N/A N/A

Does the media prefer PRTA or NBTX?

In the previous week, Prothena had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for Prothena and 3 mentions for Nanobiotix. Prothena's average media sentiment score of 1.56 beat Nanobiotix's score of 0.00 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MESO or PRTA?

Prothena has a consensus price target of $23.75, indicating a potential upside of 170.19%. Given Prothena's stronger consensus rating and higher possible upside, analysts clearly believe Prothena is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Prothena 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63

Which has higher earnings and valuation, MESO or PRTA?

Mesoblast has higher revenue and earnings than Prothena. Mesoblast is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $65.38M 27.62 -$102.14M -$0.54 N/A Prothena $9.68M 47.54 -$244.09M -$2.82 N/A

Is MESO or PRTA more profitable?

Mesoblast has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Mesoblast's return on equity of 0.00% beat Prothena's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Prothena -260.92% -43.44% -36.87%

Does the media favor MESO or PRTA?

In the previous week, Prothena had 4 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Prothena and 2 mentions for Mesoblast. Prothena's average media sentiment score of 1.56 beat Mesoblast's score of 0.18 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, PRTA or AAPG?

Ascentage Pharma Group International has higher revenue and earnings than Prothena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 47.54 -$244.09M -$2.82 N/A Ascentage Pharma Group International $82.10M 19.87 -$177.71M N/A N/A

Prothena (PRTA) Competitors

$8.79 0.00 (0.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$8.82 +0.03 (+0.32%)

As of 06:37 AM Eastern

Compare

PRTA vs. BHC, TRVI, NBTX, MESO, and AAPG

Should you buy Prothena stock or one of its competitors? MarketBeat compares Prothena with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prothena include Bausch Health Cos (BHC), Trevi Therapeutics (TRVI), Nanobiotix (NBTX), Mesoblast (MESO), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.

How does Prothena compare to Bausch Health Cos?

Prothena (NASDAQ:PRTA) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Prothena has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Bausch Health Cos has a net margin of -11.47% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

In the previous week, Prothena had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Prothena and 1 mentions for Bausch Health Cos. Prothena's average media sentiment score of 1.56 beat Bausch Health Cos' score of 0.90 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bausch Health Cos	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prothena presently has a consensus price target of $23.75, suggesting a potential upside of 170.19%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 48.84%. Given Prothena's stronger consensus rating and higher possible upside, analysts clearly believe Prothena is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Bausch Health Cos has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	47.54	-$244.09M	-$2.82	N/A
Bausch Health Cos	$10.53B	0.19	$157M	-$3.24	N/A

97.1% of Prothena shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Prothena beats Bausch Health Cos on 10 of the 17 factors compared between the two stocks.

How does Prothena compare to Trevi Therapeutics?

Prothena (NASDAQ:PRTA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Prothena has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Prothena presently has a consensus price target of $23.75, suggesting a potential upside of 170.19%. Trevi Therapeutics has a consensus price target of $22.90, suggesting a potential upside of 71.79%. Given Prothena's higher probable upside, equities research analysts clearly believe Prothena is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Trevi Therapeutics' return on equity of -24.53% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Trevi Therapeutics	N/A	-24.53%	-23.37%

In the previous week, Prothena had 5 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Prothena and 1 mentions for Trevi Therapeutics. Prothena's average media sentiment score of 1.56 beat Trevi Therapeutics' score of 0.46 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.1% of Prothena shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Trevi Therapeutics has lower revenue, but higher earnings than Prothena. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	47.54	-$244.09M	-$2.82	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Summary

Trevi Therapeutics beats Prothena on 10 of the 16 factors compared between the two stocks.

How does Prothena compare to Nanobiotix?

Prothena (NASDAQ:PRTA) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Prothena currently has a consensus target price of $23.75, suggesting a potential upside of 170.19%. Nanobiotix has a consensus target price of $37.33, suggesting a potential upside of 5.28%. Given Prothena's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prothena is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Prothena had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for Prothena and 3 mentions for Nanobiotix. Prothena's average media sentiment score of 1.56 beat Nanobiotix's score of 0.00 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Nanobiotix's return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Nanobiotix	N/A	N/A	N/A

Prothena has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than Prothena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	47.54	-$244.09M	-$2.82	N/A
Nanobiotix	$36.87M	46.66	-$27.11M	N/A	N/A

97.1% of Prothena shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Prothena beats Nanobiotix on 8 of the 14 factors compared between the two stocks.

How does Prothena compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Prothena had 4 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Prothena and 2 mentions for Mesoblast. Prothena's average media sentiment score of 1.56 beat Mesoblast's score of 0.18 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Mesoblast has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, Prothena has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Mesoblast has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Mesoblast's return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Prothena	-260.92%	-43.44%	-36.87%

Mesoblast has higher revenue and earnings than Prothena. Mesoblast is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$65.38M	27.62	-$102.14M	-$0.54	N/A
Prothena	$9.68M	47.54	-$244.09M	-$2.82	N/A

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Prothena has a consensus price target of $23.75, indicating a potential upside of 170.19%. Given Prothena's stronger consensus rating and higher possible upside, analysts clearly believe Prothena is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

Mesoblast and Prothena tied by winning 8 of the 16 factors compared between the two stocks.

How does Prothena compare to Ascentage Pharma Group International?

Prothena (NASDAQ:PRTA) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Prothena has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

97.1% of Prothena shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Prothena had 6 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 6 mentions for Prothena and 0 mentions for Ascentage Pharma Group International. Prothena's average media sentiment score of 1.56 beat Ascentage Pharma Group International's score of 0.00 indicating that Prothena is being referred to more favorably in the media.

Company	Overall Sentiment
Prothena	Very Positive
Ascentage Pharma Group International	Neutral

Ascentage Pharma Group International has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Ascentage Pharma Group International's return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Ascentage Pharma Group International	N/A	N/A	N/A

Prothena currently has a consensus price target of $23.75, suggesting a potential upside of 170.19%. Ascentage Pharma Group International has a consensus price target of $46.67, suggesting a potential upside of 166.99%. Given Prothena's higher possible upside, research analysts plainly believe Prothena is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Ascentage Pharma Group International has higher revenue and earnings than Prothena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	47.54	-$244.09M	-$2.82	N/A
Ascentage Pharma Group International	$82.10M	19.87	-$177.71M	N/A	N/A

Summary

Ascentage Pharma Group International beats Prothena on 9 of the 15 factors compared between the two stocks.

Get Prothena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTA vs. The Competition

Export

Metric	Prothena	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$460.16M	$3.33B	$6.46B	$11.98B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	-3.12	19.02	23.85	23.62
Price / Sales	47.54	297.09	512.48	110.29
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.69	7.97	10.27	6.66
Net Income	-$244.09M	$23.89M	$3.57B	$337.72M
7 Day Performance	-8.34%	-5.14%	-0.94%	-3.74%
1 Month Performance	-18.08%	2.54%	3.53%	0.95%
1 Year Performance	62.48%	36.80%	23.78%	25.35%

Prothena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTA Prothena	3.0234 of 5 stars	$8.79 flat	$23.75 +170.2%	+62.5%	$460.16M	$9.68M	N/A	130	Positive News Analyst Upgrade Insider Trade Gap Up
BHC Bausch Health Cos	3.4602 of 5 stars	$5.47 -0.1%	$8.00 +46.4%	+13.2%	$2.04B	$10.27B	N/A	20,300
TRVI Trevi Therapeutics	3.2798 of 5 stars	$14.13 flat	$22.90 +62.1%	+88.8%	$2.01B	N/A	N/A	20	Gap Up
NBTX Nanobiotix	2.2428 of 5 stars	$41.01 flat	$26.67 -35.0%	+652.9%	$1.99B	$36.87M	N/A	100	Gap Up
MESO Mesoblast	1.0861 of 5 stars	$15.20 flat	N/A	+18.3%	$1.97B	$17.20M	N/A	80	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prothena (PRTA) Competitors

PRTA vs. BHC, TRVI, NBTX, MESO, and AAPG

How does Prothena compare to Bausch Health Cos?

Summary

How does Prothena compare to Trevi Therapeutics?

Summary

How does Prothena compare to Nanobiotix?

Summary

How does Prothena compare to Mesoblast?

Summary

How does Prothena compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prothena (PRTA) Competitors

PRTA vs. BHC, TRVI, NBTX, MESO, and AAPG

How does Prothena compare to Bausch Health Cos?

Which has more volatility and risk, PRTA or BHC?

Is PRTA or BHC more profitable?

Does the media refer more to PRTA or BHC?

Do analysts prefer PRTA or BHC?

Which has stronger valuation & earnings, PRTA or BHC?

Do institutionals & insiders hold more shares of PRTA or BHC?

Summary

How does Prothena compare to Trevi Therapeutics?

Which has more risk and volatility, PRTA or TRVI?

Do analysts rate PRTA or TRVI?

Is PRTA or TRVI more profitable?

Does the media prefer PRTA or TRVI?

Do insiders and institutionals hold more shares of PRTA or TRVI?

Which has higher valuation and earnings, PRTA or TRVI?

Summary

How does Prothena compare to Nanobiotix?

Do analysts rate PRTA or NBTX?

Does the media prefer PRTA or NBTX?

Is PRTA or NBTX more profitable?

Which has more volatility and risk, PRTA or NBTX?

Which has stronger earnings & valuation, PRTA or NBTX?

Do insiders & institutionals hold more shares of PRTA or NBTX?

Summary

How does Prothena compare to Mesoblast?

Does the media favor MESO or PRTA?

Which has more volatility and risk, MESO or PRTA?

Is MESO or PRTA more profitable?

Which has higher earnings and valuation, MESO or PRTA?

Do insiders and institutionals have more ownership in MESO or PRTA?

Do analysts recommend MESO or PRTA?

Summary

How does Prothena compare to Ascentage Pharma Group International?

Which has more volatility and risk, PRTA or AAPG?

Do insiders & institutionals believe in PRTA or AAPG?

Does the media refer more to PRTA or AAPG?

Is PRTA or AAPG more profitable?

Do analysts rate PRTA or AAPG?

Which has better earnings & valuation, PRTA or AAPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA vs. The Competition

Prothena Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools